Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) has closed the second and final tranche of its previously announced private placement offering of its units.
Under the offering, Innocan issued 4,005,408 units at $0.30 per unit for aggregate gross proceeds of $1,201,622.
The company issued an aggregate of 5,425,608 units under the offering for aggregate gross proceeds of $1,627,682.
Research Capital Corporation leads the offering as sole agent and sole book-runner, Innocan said on Friday.
The Details
Each unit is comprised of one common share of the company and one purchase warrant of the company.
Each warrant shall entitle the holder thereof to purchase one common share at an ...